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Psychostimulants are used for the treatment of excessive daytime sleepiness in a wide range 
of sleep disorders as well as in attention deficit hyperactivity disorder or cognitive 
impairment in neuropsychiatric disorders. Here, we tested in mice the wake-promoting 
properties of NLS-4 and its effects on the following sleep as compared with those of 
modafinil and vehicle. C57BL/6J mice were intraperitoneally injected with vehicle, NLS-4 
(64 mg/kg), or modafinil (150 mg/kg) at light onset. EEG and EMG were recorded 
continuously for 24 h after injections and vigilance states as well as EEG power densities 
were analyzed. NLS-4 at 64 mg/kg induced significantly longer wakefulness duration than 
modafinil at 150 mg/kg. Although no significant sleep rebound was observed after sleep 
onset for both treatments as compared with their vehicles, modafinil-treated mice showed 
significantly more NREM sleep when compared to NLS-4. Spectral analysis of the NREM 
EEG after NLS-4 treatment indicated an increased power density in delta activity (0.75–3.5 
Hz) and a decreased power in theta frequency range (6.25–7.25 Hz), while there was no 
differences after modafinil treatment. Also, time course analysis of the delta activity showed 
a significant increase only during the first 2 time intervals of sleep after NLS-4 treatment, 
while delta power was increased during the first 9 time intervals after modafinil. Our results 
indicate that NLS-4 is a highly potent wake-promoting drug with no sign of hypersomnia 
rebound. As opposed to modafinil, recovery sleep after NLS-4 treatment is characterized by 
less NREM amount and delta activity, suggesting a lower need for recovery despite longer 
drug-induced wakefulness. 
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INTRODUCTION 
 
Excessive daytime sleepiness (EDS) is a major symptom of a wide range of sleep disorders. Clinical 
management of EDS includes the use of psychostimulants such as modafinil and methylphenidate. With 
increasing number of patients with EDS there is an increasing interest and need for wake-promoting 
drugs with high eﬃcacy and low side eﬀects. Modafinil is the gold standard stimulant for the treatment of 
EDS in narcolepsy and other hypersomnias (Mayer et al., 2015; Barateau et al., 2016). The mechanism 
of action of modafinil is still unclear, but evidence indicates that it 
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diﬀers from amphetamine in structure, neurochemical profile, 
and behavioral eﬀects (Minzenberg and Carter, 2008). Studies 
suggest that although inhibition of dopamine (DA) reuptake may 
be a primary mechanism underlying modafinil’s therapeutic 
actions, non-DA-dependent actions may be playing a role in its 
psychostimulant profile (Mereu et al., 2017). Moreover, beside its 
wake-promoting properties, evidence to date suggests that 
modafinil is well tolerated, safe, and lacking any of the 
euphorigenic or reinforcing properties that can lead to addiction 
(Ballon and Feifel, 2006). Pitolisant, a histamine H3 inverse 
agonist is the newest and approved second-generation stimulant 
with eﬃcacy comparable to modafinil (Dauvilliers et al., 2013). 
Another second-generation wake-promoting drug, JZP-110 is in 
advanced clinical trials for the treatment of EDS in narcolepsy 
and sleep apnea (Bogan et al., 2015; Ruoﬀ et al., 2016). JZP-
110 is a potent dopaminergic-noradrenergic drug with eﬃcacy 
higher than modafinil (Hasan et al., 2009). Lauflumide [2-((bis(4-
fluorophenyl)methane)sulfinyl)acetamide] (NLS-4) was 
conceptualized by the R&D of Laboratoire L. Lafon but has never 
been developed. This bis (p-fluoro) ring-substituted derivative of 
modafinil (Figure 1A) is an original potent wake-promoting agent 
and produces anti-aggressive eﬀects in rats, which modafinil 
does not (Patent No.:US9,637.447B2). Preliminary findings 
suggest that NLS-4 is a selective dopamine reuptake inhibitor, 
blocking (83%) dopamine transporter (DAT), higher than 
methylphenidate and without deleterious eﬀects on peripheral 
adrenergic systems involved in hypertension (Study 100014859 
CEREP 20/03/14, unpublished data). 
 
The aim of the present study was to evaluate the wake-
promoting properties of NLS-4 in mice, its eﬀects on the 
following sleep and to compare its pharmacological eﬀects on 
vigilance states with those of modafinil and vehicle. 
 
MATERIALS AND 
METHODS Animals 
 
Adult male C57BL/6J mice (age: 10–11 weeks at the time of 
surgery; weight: 22–26 g) were purchased from Charles River. 
Mice were kept individually in polycarbonate cages (31 ×18 × 18 
cm) with food and water available ad libitum, and maintained on 
a 12 h light–dark cycle (lights on at 09:00 h) at an ambient 
temperature of 24.5–25.5
◦
C. The study protocols were approved 
by the Veterinary Oﬃce of the Canton of Vaud, Switzerland. 
 
Chemicals  
NLS-4 was synthesized in 4 steps as described in Figure 1A.  
We first determined the eﬀective dose for NLS-4. C57BL/6J 
mice (N = 8) were individually housed as described above. 
Activity was recorded under 12:12 h light-dark cycles. To 
determine the NLS-4 dose that induces a robust wakefulness 
period, locomotor activity was monitored and recorded using 
infrared sensors. ClockLab software (Actimetrics) was used for 
both data acquisition and analyses. Five NLS-4 doses were 
administrated at light onset in ascending or descending order 
every 24 h: vehicle, 32, 64 , 128, and 256 mg/kg. Sleep onset 
was defined as the time elapsed between the time of injection 
and the first inactivity episode (5 min of infrared uninterrupted 
 
 
 
inactivity). Based on dose-response analysis (Figure 1B) the dose of 
64 mg/kg was chosen. For modafinil the dose of 150 mg/kg was 
used based on our previous work (Hasan et al., 2009).  
Another set of 8 mice per treatment was randomly 
assigned to NLS-4 or modafinil treatment, receiving two 
intraperitoneal injections in a random order (drug-vehicle or 
vehicle-drug) at 24 h interval. After the 24 h baseline, mice 
received either the drug or vehicle. NLS-4 was dissolved in 
10% DMSO-saline solution. As previously described (Hasan 
et al., 2009) modafinil was not dissolved but suspended in 
the saline solution by vortexing and injecting immediately 
each mouse. Drug solutions were freshly prepared the same 
day before light onset. Control solutions (vehicle) were 10% 
DMSO-saline solution for NLS-4 and saline for modafinil. 
 
Sleep Recording and Analysis 
 
EEG and EMG electrodes implantation was performed under 
deep anesthesia as previously described (Hasan et al., 
2009). EEG/EMG signals were recorded using EMBLA 
hardware and Somnologica-3 software (Flaga, Iceland). The 
animal’s behavior was scored based on visual inspection of 
EEG and EMG signals every 4 s as wakefulness, non-rapid 
eye movement (NREM), or REM sleep.  
The EEG spectral analysis was performed as described 
previously (Vienne et al., 2010). Briefly, the EEG signal (frontal-
central) was subjected to a discrete Fourier transformation 
yielding power spectra (range: 0.25–25 Hz; resolution: 0.25 Hz; 
window function: hamming) for 4-s artifact-free epochs. Two 
mice treated with NLS-4 (N = 6) and one treated with modafinil 
(N = 7) were excluded from the analysis due to artifacts. Spectral 
composition was generated using PRANA software. The EEG 
delta power during NREM sleep was calculated by averaging 
power density in the frequency bins from 0.75 to 4 Hz (Mang and 
Franken, 2012). Values were normalized per mouse by 
expressing them as a percentage of the mean delta power over 
NREM sleep in the last 4 h of the baseline light period (when all 
mice reach the lowest 24 h level of delta power). The time 
course of EEG delta power in NREM sleep was calculated for 
the sleep following drug administration. To adjust and 
compensate for the diﬀerent amount of NREM sleep across the 
light and dark cycle, NREM amounts were subdivided into 
intervals (12 time intervals during the light period and 6 for the 
dark period; see Figure 4) with an equal number of contributing 
NREM epochs for all intervals of the respective segment (e.g., 
the durations of NREM sleep as reported in Table 1 are divided 
into 12 equal segments during the light and 6 during the dark 
period: for NLS-4 light: 254/12 = 21 min, dark: 174/6 = 29 min on 
average for each time interval). 
 
Statistical Analysis 
 
The amount of drug-induced wakefulness was analyzed by 
paired t-test (drug vs. vehicle). To directly compare the 
between drug diﬀerence in drug-induced wakefulness the 
duration of vehicle-induced wakefulness was subtracted from 
that of the drug for each mouse and the mean durations were 
analyzed by t-test (Figure 1C). The hourly amounts of NREM 
sleep after drug administration were analyzed separately 
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FIGURE 1 | (A) NLS-4 was synthesized through a straightforward method involving first a Grignard addition of the desired 4-fluorophenylmagnesium bromide onto 4-
fluorobenzaldehyde to provide p-fluorobenzydrol. Addition of thiourea in bromohydric medium, followed by treatment of the thiourea adduct with aqueous NaOH and 
alkylation with 2-chloroacetamide afforded intermediate “A.” Finally, asymmetric oxidation of thioether “A” into (R)-sulfoxide by using Kagan method (Pitchen and Kagan, 
1984) led to expected NLS-4 compound in 23% overall yield in 4 steps (Cao et al., 2010). (B) Amount of spontaneous locomotor activity measured after intraperitoneal 
administration of increasing doses of NLS-4 at light onset (N = 8). (C) Duration of EEG recorded wakefulness after administration of 64 mg/kg of NLS-4, 150 mg/kg of 
modafinil, or vehicle. Both drugs significantly increased the amount of wakefulness (paierd t-test, *P < 0.05) but NLS-4-induced wake duration was significantly higher than 
that of modafinil (t-test, *P < 0.05). 
+
indicates drug-vehicle value. 
 
 
 
 
for each drug by a 2-way repeated measures ANOVA with 
factor “treatment” (drug vs. vehicle) and “time” (time points 
after drug injection). To directly compare the between drug 
diﬀerences in NREM sleep distribution the amount of vehicle-
induced NREM sleep was subtracted from that of the drug for 
each mouse and the mean hourly values were compared by 
a 2-way ANOVA with factor “drug” (NLS-4 vs. vehicle) and 
“time” (time points after drug injection). The power densities 
during each vigilance states and the time course of the slow 
wave activity during NREM sleep were analyzed separately 
for each drug by a 2-way repeated measures ANOVA with 
factor “treatment” (drug vs. vehicle) and “frequency” 
(frequency bins in Hz) or “time” (time points after drug 
injection), respectively. To directly compare the between drug 
diﬀerences, values of drug condition were divided by those of 
vehicle for each mouse and the mean power densities were 
compared by a 2-way ANOVA with factor “drug” (NLS-4 vs. 
vehicle) and “frequency” (frequency bins in Hz), or “time” 
(time points after drug injection), respectively. All statistical 
analyses were performed with GraphPad Prism and all post-
hoc tests were Sidak corrected for multiple comparisons. 
 
 
RESULTS 
 
Vigilance States 
 
Both NLS-4 (N = 8) and modafinil (N = 8) increased the 
duration of drug-induced wakefulness compared with 
 
 
 
vehicle (Figure 1C) (paired t-test between “drug” and “vehicle” 
condition, p < 0.05, Table 1). Subtracting the vehicle-induced 
from that of drug-induced wakefulness indicated that NLS-4 
administration resulted in an overall longer wakefulness duration 
(151.18 ± 15.33 min for NLS-4 and 109.67 ± 16.59 min for 
modafinil, p < 0.05, t-test, Figure 1C). Neither NLS-4 nor 
modafinil induced hyper locomotor, stereotypic activity, or 
abnormal behavior (by direct observation, infra-red and video 
recording). The distribution of vigilance states after sleep onset 
(defined as 3 consecutive epochs of NREM sleep or 12 s) was 
aﬀected in both groups. NREM sleep amount for NLS-4 was 
significantly lower, and NLS-4-treated mice had overall less 
NREM sleep as compared with modafinil-treated group (Figure 
2). The recovery of lost NREM sleep (NREM accumulation minus 
vehicle) at the end of the light 
period  (12 h after drug administration) indicated a  deficit 
of 87.61 ± 36.78 min for NLS-4 and of 45.04 ± 19.96 min 
for modafinil-treated mice. For modafinil-treated group the 
recovery of lost NREM sleep  further continued to the  
dark period, leading into a significantly larger amount of 
accumulated NREM sleep at the end of the 24 h recording 
(Table 1).  
For both NLS-4 and modafinil-treated groups, REM sleep 
amount was decreased during the light and increased during 
the dark recovery period, as compared to vehicle (Figure 2, 
Table 1). The analysis of vigilance states bout duration and 
number indicated no significant diﬀerences between drugs or 
between drugs and vehicles.  
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TABLE 1 | Distribution of vigilance states during the 24 h after drug administration.  
 
  NLS-4 (N = 8) Vehicle (N = 8) Modafinil (N = 8) Vehicle (N = 8) NLS-4 vs. 
          Modafinil 
           
          P 
Sleep latency after  208.18 ± 12.99***
a 
55.92 ± 11.52 178.25 ± 12.59***
a 
56.18 ± 9.82 <0.05
b 
drug injection           
NREM Light 254.41 ± 21.16***
c 
342.02 ± 22.67 292.73 ± 29.86***
c 
337.76 ± 23.06 <0.05
d 
 Dark 174.86 ± 49.90 158.50 ± 37.10 206.81 ± 32.70**
c 
178.94 ± 28.13 ns
d 
REM Light 40.67 ± 6.94**
c 
49.84 ± 6.14 41.41 ± 10.42**
c 
45.74 ± 11.23 <0.05
d 
 Dark 21.88 ± 10.12*
c 
16.71 ± 7.67 20.95 ± 5.95***
c 
14.29 ± 7.85 ns
d 
Wake Light 223.30 ± 37.57**
c 
273.37 ± 19.28 226.21 ± 52.35**
c 
285.73 ± 25.42 ns
d 
 Dark 523.25 ± 58.66 544.79 ± 44.03 490.26 ± 35.98 525.83 ± 34.54 ns
d 
NREM sleep loss Light −87.61 ± 36.78   −45.04 ± 19.96   <0.05
d 
 Dark −71.25 ± 23.55   −17.17 ± 51.43   <0.05
d 
REM sleep loss Light −9.18 ± 3.88   −4.33 ± 4.37   <0.05
d 
 Dark −4.23 ± 1.50   2.32 ± 6.33   <0.01  
 
All values are mean ± SD. 
*
 P< 0.05, 
**
 P< 0.01, 
***
 P< 0.001.  
a Paired t-test. 
b
t-test.
 
c
2-way repeated measures ANOVA. 
d
 2-way ANOVA, ns: non-significant. NREM and REM sleep losses correspond to the differences of accumulated sleep between drugs and their respective vehicles at the end 
of the light and dark period. 
 
 
EEG Spectral Composition After the Drug 
Administration  
The EEG spectral composition did not diﬀer at baseline or during 
vehicle administration between the two drugs. We compared NREM, 
REM and Wake relative power densities to evaluate the diﬀerences 
between vehicle and drug (2-way repeated measures ANOVA, 
factors “drug,” “bin (Hz),” and their interaction). Also, the spectral 
composition was compared between the two drugs. A similar 
analysis was also performed for absolute power densities. 
 
NREM Sleep 
 
NLS-4 induced an increase in 0.75–3.25 Hz frequency range, 
and lower relative power in 6.25–7.25 Hz frequency range 
(Figure 3). No significant diﬀerences in overall spectral 
composition were identified for modafinil-treated mice. Analysis 
of absolute power densities confirmed that only NLS-4 increased 
delta power. Between drug comparisons did not reveal any 
significant drug or interaction eﬀect (Supplementary Figure 1). 
 
REM Sleep and Wake 
 
Only NLS-4 induced a decrease in relative theta power densities 
during REM sleep (Figure 3). A similar decrease was also found 
for the absolute power densities (Supplementary Figure 1).  
NLS-4 induced a significant increase in the relative low 
delta power during wakefulness while modafinil had no 
eﬀect (Figure 3). Similarly, NLS-4 treatment induced an 
increase in absolute power in low delta frequencies during 
wakefulness, while modafinil-treated mice showed lower 
absolute power at 8.25 Hz only (Supplementary Figure 1). 
 
EEG Delta Power During NREM Sleep 
 
Sleep following the drug-induced wakefulness showed a 
significant increase in delta power. Delta power was increased  
 
 
only for the first 2 time intervals for NLS-4-treated mice 
(Figure 4), while modafinil treatment resulted in increased 
delta power for the first 9 time points and time point 12. The 
overall diﬀerence in NLS-4 treated mice was significantly 
lower than in modafinil-treated ones (Figure 4). 
 
Spectral Composition of Drug-Induced Wakefulness 
 
The comparison between drug-induced and vehicle-induced 
wakefulness showed only an increase in low delta power [2-
way repeated measures ANOVA, NLS-4: “treatment” p > 0.1, 
F(1, 5) = 2.5, “bin” p < 0.001, F(97, 485) = 46.23, interaction 
p <  0.05, F(97, 485)  =  1.31, modafinil: “treatment” p >  0.7, 
F(1, 6) =  0.07, “bin” p < 0.001, F(97, 582) =  39.25, interaction 
p < 0.01, F(97, 582) =  1.46, multiple comparisons: p < 0.05 for 
0.75 Hz with drug>vehicle]. 
 
DISCUSSION 
 
We compared vigilance states and spectral power densities during 
and after administration of NLS-4 and modafinil in mice. NLS-4 was 
found to be a highly potent wake-promoting drug with less than half 
of the modafinil dose resulting in significantly longer wakefulness. No 
significant changes in behavior (signs of hyper locomotor activity) 
were found either under NLS-4 or modafinil. Rebound hypersomnia 
(over compensation), typically found with amphetamine or 
methyphenidate (Gruner et al., 2009; Hasan et al., 2009), was not 
observed for either drugs. Nevertheless, more sleep was found after 
wake-induced period by modafinil as compared to NLS-4. Spectral 
analysis of wakefulness during and sleep after drug-induced 
wakefulness revealed that both drugs increased EEG power 
densities within the slow frequencies (<4 Hz) but the increase by 
NLS-4 was significantly 
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FIGURE 2 | Hourly distribution of vigilance states after NLS-4, modafinil, and vehicle administration (mean±SEM). After initial suppression of NREM sleep by both 
drugs [2-way repeated measures ANOVA, NLS-4: “treatment” p < 0.0001, F(1, 7) = 73.25, “hour”, p < 0.0001, F(23, 161) = 17.21, interaction, p < 0.0001, 
F (23, 161)= 4.16; modafinil: “treatment” p > 0.38, F(1, 7) = 0.89, “hour” p < 0.0001, F(23, 161) = 20.18; interaction, p < 0.0001, F(23, 161) = 5.10], the distribution  
of NREM sleep during recovery is very similar to that after vehicle indicating the absence of sleep rebound (hypersomnia). Nevertheless, comparisons between the two drugs 
indicated significantly less NREM sleep after NLS-4 administration as compared to modafinil [2-way ANOVA, drug effect: F(1, 14) = 7.31, p < 0.02]. REM sleep is also 
suppressed during the first hours after drug injection while wakefulness is increased. Upward and downward triangles indicate significant increase or decrease, respectively. 
Shaded areas indicate the dark period. 
+
indicates drug/vehicle ratio.  
 
 
lower than modafinil despite the fact that NLS-4 induced a longer 
wakefulness amount. Although NLS-4 is a derivative of modafinil, 
our results indicate that not only is it more potent than modafinil 
at the doses tested but also wakefulness induced by NLS-4 is 
compensated by less NREM sleep as well as delta power. 
 
Drug Effects on Wakefulness Amount 
 
Our dose-response study based on spontaneous locomotor 
activity indicated a substantial increase in NLS-4-induced  
 
 
wakefulness up to 64 mg/kg but no further increment at 128 and 
256 mg/kg. We previously reported that modafinil increased 
wakefulness in a linear manner between 100 and 300 mg/kg 
(Hasan et al., 2009). The dose of 64 mg/kg was chosen for NLS-
4 because this dose induced 4 h of wakefulness (Figures 1C, 2) 
similar to our previous report with modafinil at 150 mg/kg (Hasan 
et al., 2009). Sleep recordings indicated a large increase in 
wakefulness during the first 4 h after both NLS-4 and modafinil 
administration as compared to vehicle and NLS-4 at 64 mg/kg 
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FIGURE 3 | Relative spectral profiles of wake, NREM and REM sleep after drug-induced wakefulness (from sleep onset till the end of the 24 h recording). No changes were 
observed between modafinil and vehicle while NLS-4 showed increased power densities in delta frequency range [2-way repeated measures ANOVA, “treatment” p > 0.65, 
F(1, 5) = 0.22, “bin” p < 0.0001, F(97, 485) = 133.60, interaction p < 0.0001, F(97, 485) = 6.66]. Additionally, theta power density was decreased during NREM and REM 
sleep under NLS-4 treatment [2-way repeated measures ANOVA, “treatment”, p > 0.16, F(1, 5) = 2.57, “bin” p < 0.0001,  
F (97, 485) = 736.60, interaction p < 0.0001, F(97, 485) = 4.28; multiple comparisons: p < 0.05 for: 6.5–7.75 Hz, with drug<vehicle]. Low delta power was increased during wakefulness 
after NLS-4 treatment while no changes were observed after modafinil [2-way repeated measures ANOVA, NLS-4: “treatment” p > 0.28,  
F (1, 5) = 1.45, “bin” p < 0.0001, F(97, 485) = 64.03, interaction p < 0.01, F(97, 485) = 1.55, multiple comparisons: p < 0.05 for: 0.75–1.25 Hz, with drug>vehicle and 4.25 Hz, with 
drug<vehicle]. Upward and downward triangles indicate significant increase or decrease in power, respectively.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 4 | Time course of slow-wave (delta) activity (0.75–4 Hz) during NREM sleep following drug-induced wakefulness. Delta power is increased during the first 2 time 
intervals of sleep after NLS-4 [2-way repeated measures ANOVA, “treatment” p > 0.9, F(1, 5) = 0.01, “hour” p < 0.001, F(17, 85) = 11.79, interaction p < 0.001,  
F (17, 85) = 5.04] and during the first 9 time intervals after modafinil administration [2-way repeated measures ANOVA, “treatment” p < 0.05, F(1, 6) = 9.35, “hour” p < 0.001, F(17, 
102) = 17.88, interaction p < 0.05, F(17, 102) = 2.04]. Comparison between drugs indicates an overall increased spectral power after modafinil administration [2-way ANOVA, “drug” p < 
0.05, F(1, 11) = 5.23, “hour” p < 0.001, F(17, 187) = 4.39, interaction p = ns, F(17, 187) = 0.93]. Upward and downward triangles indicate significant increase or decrease in delta power, 
respectively. Shaded areas indicate the dark period.  
 
 
 
induced significantly longer wakefulness duration as 
compared to modafinil at 150 mg/kg. These results 
indicate that NLS-4 is more potent wake-promoting drug 
than modafinil at the doses tested.  
 
 
 
Drug Effects on EEG During Induced 
Wakefulness  
One important aspect of any stimulant is the quality of the 
induced wakefulness. Our direct observations (visually and by 
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video) did not reveal any hyperactivity under NLS-4 or 
modafinil. We next analyzed the EEG during drug-induced 
wakefulness. As compared with vehicle, waking induced by 
NLS-4 as well as modafinil showed a significant increase in 
low delta activity only. This finding is consistent with the drug-
induced long wakefulness duration. Since no other significant 
changes were observed, we conclude that both drugs 
produce similar and normal wakefulness. 
 
Drug Effects on Recovery Sleep 
 
The eﬀects of both NLS-4 and modafinil disappeared after 4 and 
2 h and from this point on there were no significant diﬀerences 
between the drug and the vehicle condition (except a slight 
increase in NREM sleep at hour 19 under modafinil). This 
indicates that none of these drugs induce rebound hypersomnia. 
Rebound hypersomnia is a well-established side eﬀect of the 
classical stimulants such as amphetamine, methamphetamine, 
and phentermine (Gruner et al., 2009; Hasan et al., 2009). It was 
suggested that this side eﬀect is due to increased release of 
cathecholamines, especially dopamine, while dopamine reuptake 
blockers do not present such an undesirable side eﬀect (Gruner 
et al., 2009). Nevertheless, cocaine, bupropion, and 
methylphenidate (dopamine active transporter inhibitors) also 
induce rebound hypersomnia, suggesting that other mechanisms 
(such as pharmacokinetic) are involved (Gruner et al., 2009). 
Other stimulants such as mazindol and JZP-110 are lacking the 
rebound hypersomnia and must act as dopamine transporter 
inhibitors (Gruner et al., 2009; Hasan et al., 2009). It was also 
suggested that some stimulants such as cocaine produce late 
hypersomnia (12–24 h after administration) (Dugovic et al., 
1992). NLS-4 not only did not induce late NREM sleep rebound 
but even induced a decrease in the middle of the dark period 
with a significant decrease in delta power (18 h after drug 
administration), while modafinil induced a significant increase in 
NREM sleep at hour 19 (7 h into the dark period) as compared 
with vehicle. Comparison of recovery sleep between the two 
drugs revealed significantly less NREM sleep after NLS-4 
administration (Figure 2), suggesting that less NREM sleep is 
accumulated (or compensated) during first hours of recovery 
after NLS-4 as compared to modafinil. 
 
 
Drug Effects on the Recovery Sleep EEG 
 
Modafinil did not change any aspects of the waking EEG spectral 
powers during the recovery period while NLS-4 induced 
increased low delta and decreased high delta (Figure 3). Power 
densities within the delta range were significantly increased 
during recovery NREM sleep after NLS-4 while theta power 
density was decreased. Modafinil did not induce any significant 
changes. Overall, NLS-4 significantly increased power densities 
when compared to vehicle, strongly suggesting that recovery 
after NLS-4 occurred principally through an increase in sleep 
intensity. Only NLS-4 induced decreased power densities in high 
theta range (6.5–7.25 Hz) during REM sleep, as compared with 
vehicle. The significance of the changes in the theta range 
during both NREM and REM sleep remains unknown. 
 
The time course analysis of the delta activity during NREM 
sleep (an index of sleep homeostasis) indicated a significant  
 
 
increase (during the first 2 time intervals of recovery sleep) after 
NLS-4 and more after modafinil (first 9 time intervals of recovery 
sleep). Interestingly, mice slept less during this period after NLS-
4 confirming that recovery after NLS-4-induced wakefulness 
occurred with less NREM amount and less delta activity. Another 
interesting observation is that although animals under NLS-4 
stayed awake longer, delta activity was increased during a 
longer period in modafinil treated animals after sleep onset, 
suggesting that recovery occurred faster after NLS-4. 
 
In summary, NLS-4 is a potent stimulant with diﬀerent 
eﬀects than its parent compound modafinil (Rambert et 
al., 1986) and most other stimulants in terms of potency 
and eﬀects on sleep rebound and the sleep EEG. 
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Supplementary Figure 1 | Absolute spectral profiles of wake, NREM and REM 
sleep after drug-induced wakefulness. NLS-4 showed increased power densities in 
delta frequency range during wakefulness and NREM sleep and decreased power 
densities in theta frequency range [NLS-4: 2-way repeated measures ANOVA, 
“treatment” p > 0.11; F(1, 5) = 3.66, “bin” p < 0.0001, F (97, 485) = 
46.43, interaction p < 0.0001, F(97, 485) =5.80; multiple comparisons: p < 0.05  
for: 0.75–4.00 Hz, with drug>vehicle]. Low delta power was increased during 
wakefulness after NLS-4 treatment [2-way repeated measures ANOVA, 
“treatment” p > 0.5; F(1,5) = 0.51, “bin” p < 0.0001, F(97, 485) = 24.20, 
interaction p < 0.001, F(97, 485) = 1.59; multiple comparisons: p < 0.05 for: 
0.75–1.25 Hz, with drug>vehicle] while modafinil induced lower absolute power at 
8.25 Hz [2-way repeated measures ANOVA, “treatment” p > 0.39, F(1, 6) = 0.84, 
“bin” p < 0.0001, F(97, 582) = 20.90, interaction p < 0.01, F(97, 582) = 1.43; 
multiple comparisons: p < 0.05 for 8.25 Hz, with drug>vehicle]. Upward and 
downward triangles indicate significant increase or decrease in power, respectively. 
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